Aerie Pharma (AERI) Misses Q2 EPS by 1c

Aerie Pharma (NASDAQ: AERI) reported Q2 EPS of ($0.63), $0.01 worse than the analyst estimate of ($0.62).

“This has been a highly productive period for Aerie, and we are actively engaged in all facets of commercialization preparation as we look to make our RhopressaTM launch as successful as possible, upon approval. For our RoclatanTM program, we also recently completed the Mercury 1 12-month study, and we look forward to the upcoming commencement of the Mercury 3 trial in Europe. Our recent agreement with DSM also continues our journey into treating retinal disease, and we are very excited about the potential of this early program as well,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer.

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c